Collegium Pharmaceutical (COLL) Q3 2026 earnings review
Collegium's ADHD sales climb, but its pain business shrinks faster
Collegium Pharmaceutical, a maker of ADHD and pain medicines, grew its ADHD franchise while its older pain drugs shrank faster. Total revenue edged up 3% only because of newly acquired Azstarys; by our math, sales from drugs owned a year ago fell 9% as pain revenue dropped 18%. Chief executive Vikram Karnani kept the full-year outlook unchanged, which by our math leaves fourth-quarter adjusted EBITDA down 7% from a year ago.
| Sales from drugs owned a year ago | -9% reported revenue +3% to $216.3M |
|---|---|
| Jornay PM net revenue | $51.9M +24% from a year ago; prescriptions +16% |
| Profit per share, excluding one-offs | $1.96 -13% from a year ago |
| Full-year 2026 outlook | Unchanged middle of the range: $840M sales, $457.5M adjusted EBITDA |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because faster ADHD prescription growth and a steeper pain decline canceled each other out. Jornay PM prescriptions rose 16%, reversing a five-quarter slowdown, and Azstarys returned to prescription growth in its first full quarter under Collegium. On the other side, Nucynta sales fell another 13% from last quarter, and higher sales overhead pushed profit down.
The question now is whether the two ADHD medicines can grow fast enough to replace the high-margin pain cash flows before generic rivals enter in 2027. Optimists point to rising doctor adoption and a 30% market share for Jornay PM, while skeptics see shrinking pain sales and higher overhead eating into profit. Fourth-quarter Azstarys sales and the 2027 outlook in February will show which side is right.
🐂 Bull Case
Jornay PM Prescription Growth Turned Back Up
Jornay PM, Collegium's evening-dosed medicine for attention-deficit hyperactivity disorder (ADHD), drives the company's shift away from pain treatments. Critics worried that prescription growth had slowed for five straight quarters and that revenue relied on narrower rebate discounts rather than patient demand. Chief executive Vikram Karnani said, "We continued to see strong demand across our ADHD portfolio, supported by expanded commercial efforts heading into the back-to-school season."
- Jornay PM net revenue: $51.9 million, up 24% from a year ago
- Quarterly prescriptions: 223,000, up 16% from a year ago after 13.1% growth last quarter
- Prescribing doctors: nearly 33,000, up 19% from a year ago
- Brand market share: 30% of long-acting methylphenidate prescriptions, up 6.5 percentage points
The prescription rebound matters because Jornay PM lapped last year's rebate improvement this quarter. Revenue grew 8 percentage points faster than prescriptions by our math, down from 28 points last quarter, so volume carried two-thirds of the gain. What to watch: fourth-quarter Jornay PM sales against the $58.1 million implied by the full-year outlook. Beating that figure would show the expanded sales force is lifting prescriptions per doctor.
Azstarys Returned to Prescription Growth in First Full Quarter
Collegium bought Azstarys, a once-daily ADHD capsule combining fast-acting and long-acting ingredients, in May 2026 to sell alongside Jornay PM. In its first full quarter under the drugmaker's ownership, Azstarys generated $26.5 million in net revenue and 190,000 prescriptions, up nearly 2% from a year ago. Karnani called that a "meaningful improvement from AZSTARYS’ annual prescription decline in 2025, prior to its acquisition by Collegium".
Together, the two ADHD medicines brought in $78.4 million, or 36% of total company sales. That clears the quarterly run-rate before the acquisition, but the full-year plan still asks for more. What to watch: fourth-quarter Azstarys revenue, which must reach $30.6 million by our math to hit the middle of the $65 million to $75 million full-year target. Reaching that mark would confirm that doctor adoption is accelerating.
Management Launched a $50 Million Share Buyback
Collegium had left its $150 million share buyback authorization untouched for a full year while it conserved cash to buy Azstarys. In August, the biopharmaceutical group signed a $50 million accelerated share repurchase agreement and received an initial delivery of 1.56 million shares, leaving $100 million on the authorization through December. Finance chief Colleen Tupper said the buyback will finish before year-end, "underscoring our confidence in the company’s long-term growth prospects".
The repurchase trimmed diluted share count by 0.8% from a year ago, to 39.1 million shares, because the company bought the shares midway through the quarter. What to watch: whether the board renews or uses the remaining $100 million authorization before it expires on December 31, 2026. Choosing debt paydown instead would show management is prioritizing its credit facility over further share reductions.
🐻 Bear Case
Pain Franchise Drop Pulled Underlying Sales Down 9%
Collegium relies on three opioid pain treatments — Belbuca, Xtampza ER and the Nucynta franchise — to fund its expansion and debt payments. Karnani said in the release that "Our pain portfolio also continues to provide a strong financial foundation". The quarter's numbers cut against that framing, because pain sales fell 18% from a year ago to $138.0 million, pulling sales from drugs owned a year ago down 9.3% by our math.
- Nucynta franchise: $30.8 million, down 44% from a year ago and down 12.5% from last quarter
- Xtampza ER (extended-release oxycodone): $45.8 million, down 9% from a year ago
- Belbuca (buprenorphine film): $57.7 million, down 1% from a year ago after 10% growth last quarter
Nucynta is shrinking because partner Hikma sells authorized generic versions that return a fraction of the branded price, and Belbuca stopped growing just ahead of its January 2027 generic settlement date. What to watch: fourth-quarter Nucynta revenue against this quarter's $30.8 million level. Another sequential drop would show that authorized generic pricing has not yet stabilized.
Higher Overhead and Pain Erosion Cut Profit
Collegium promised that buying Azstarys would add to adjusted EBITDA (earnings before interest, taxes, depreciation, amortization and one-offs) right away and unlock more than $50 million in annual cost savings within a year. Instead, third-quarter adjusted EBITDA fell 8.6% from a year ago to $121.6 million, and the adjusted EBITDA margin shrank by 7.3 percentage points to 56.2% by our math.
Overhead drove the drop: selling, general and administrative expenses (advertising, sales force and corporate overhead) rose 14.0 percentage points of revenue to 46.0%, and operating expenses excluding one-offs rose 25% to $69.4 million, or 5.5 points of revenue. A $9.7 million accounting charge for acquired Azstarys inventory also cut gross margin by 3.7 points. What to watch: fourth-quarter operating expenses excluding one-offs, where a drop below $69.4 million would show deal savings are arriving.
Risks this quarter didn't answer
Five standing concerns from prior quarters received no new disclosures in the third-quarter earnings release or slide presentation.
- 2027 pain patent expirations: Teva holds rights to launch generic Belbuca in January 2027 and Nucynta exclusivity expires in 2027; the conference call or quarterly filing will show any updated defenses.
- Ironshore arbitration: a pre-acquisition claim seeking over $500 million against the Jornay PM subsidiary had no update; the quarterly filing's legal footnote will carry any status change.
- Xtampza ER patent litigation: no update in the release, though Collegium booked $11.0 million in unspecified litigation settlements this quarter; the legal footnote will identify the case.
- Jornay PM peak sales target: management again gave no long-term revenue ceiling for its lead ADHD medicine.
- Rare-disease acquisition plans: management announced no new deals and gave no update on its search criteria.
👓 Other Themes
Tax Law Change Lifted Reported Net Profit
Collegium reported $21.8 million in net income, down 31% from a year ago, even though pre-tax profit fell 82% to $7.9 million. A $21.0 million one-time tax benefit from a change in tax law created a $13.9 million net tax credit for the quarter. Without that tax benefit, net income was $0.8 million by our math, because litigation charges of $11.0 million and acquisition costs weighed on pre-tax profit.
💲 Other KPIs
Cash generated from operations rose 10.3% from a year ago by our math, up from $71.3 million last quarter and $57.1 million in the first quarter. Operating cash flow grew even as operating profit fell, because non-cash amortization, stock compensation and deferred tax credits did not drain cash.
Total debt of $1,081.5 million less $144.8 million of cash left net debt at $936.7 million by our math, or 2.1 times trailing adjusted EBITDA. Leverage stayed unchanged from the second quarter after rising from under 1.0 times at the end of 2025 to fund the Azstarys purchase.
Uncollected bills from wholesalers rose 47.1% from the end of 2025 and 32.8% from a year ago by our math, far outpacing the 3.3% revenue increase. Adding Azstarys expanded both receivables and accrued rebates, returns and discounts, which climbed 34.2% from year-end to $427.2 million.
🔮 Guidance
Unchanged. The full-year plan still calls for 7.6% revenue growth at the $840 million middle of the range, after Collegium cut the target by $40 million last quarter on lower Nucynta generic pricing. By our math, that leaves $230.3 million for the fourth quarter, or 12.1% growth from a year ago, though sales excluding Azstarys would still shrink 2.8%.
Unchanged. Management kept the target it lowered by $27.5 million last quarter, putting full-year adjusted EBITDA down 0.7% at the $457.5 million middle of the range. By our math, that leaves $118.2 million for the fourth quarter, down 7.2% from $127.3 million a year ago and below the third quarter's $121.6 million.
Unchanged. The drugmaker held its target for a third straight quarter, pointing to 31.0% full-year growth at the $195 million middle of the range. With $136.9 million booked in the first nine months, the plan leaves $58.1 million for the fourth quarter by our math, up 26.6% from a year ago.
Unchanged. After raising the partial-year target by $5 million last quarter, Tupper kept the range at $65 million to $75 million for the period from the May 12 close through December. With $39.4 million recorded so far, the middle of the range leaves $30.6 million for the fourth quarter by our math, up from $26.5 million in the third quarter.
❓ Key Questions
Has Nucynta authorized generic pricing still not hit bottom?
Management said in August that Nucynta authorized generic pricing had stabilized, yet total Nucynta revenue fell another 12.5% from the second quarter to $30.8 million, andHikma profit-share payments dropped from $5.1 million to $4.2 million.
What caused the $11 million litigation charge this quarter?
Collegium booked $11.0 million in litigation settlements and contingencies in the third quarter, up from zero in the first half, while facing opioid investigations, Xtampza patent suits and a $500 million Ironshore arbitration.
Why does the outlook imply lower fourth-quarter profit?
By our math, the middle of the full-year outlook puts fourth-quarter adjusted EBITDA at $118.2 million, down from $121.6 million in the third quarter, even though revenue is set to rise by $13.9 million.
What were Jornay PM and Azstarys rebate rates?
The release did not disclose gross-to-net rebate percentages for either ADHD medicine, leaving unclear how much of Jornay PM's 24% revenue growth came from pricing and whether Azstarys improved from its 74% initial discount rate.